Emerging Therapeutic Avenues in Metastatic Colorectal Cancer Pipeline: An Extensive Assessment of 130+ Key Companies Driving Progress | Arcus Biosciences, SFJ Pharmaceuticals, Merck Serono, and others
(Albany, United States) As per DelveInsight’s assessment, globally, the Metastatic Colorectal Cancer Pipeline constitutes 130+ key companies continuously working towards developing 140+ Metastatic Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Metastatic Colorectal Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Colorectal Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Metastatic Colorectal Cancer pipeline treatment landscape of the report, click here @ Metastatic Colorectal Cancer Pipeline Outlook
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
- DelveInsight’s Metastatic Colorectal Cancer Pipeline analysis depicts a robust space with 130+ active players working to develop 140+ pipeline treatment therapies.
- The leading Metastatic Colorectal Cancer Companies in the market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merc, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others
- Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, Oxaliplatin, Leucovorin, Binimetinib, Oxaliplatin, CYAD-101, FOLFOX, Pembrolizumab, Aflibercept, Levofolinate, Irinotecan, and others.
- On March 2023, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals Inc announced a study of phase 1 & 2 clinical trials for ZN-c3, Encorafenib, and Cetuximab. The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
- On May 2023, Arcus Biosciences Inc announced a study of phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, Bevacizumab and Regorafenib. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
- On June 2023, Bristol-Myers Squibb announced a study of phase 3 clincial trials for Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, and Cetuximab. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
Metastatic Colorectal Cancer Overview
Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ.
To explore more information on the latest breakthroughs in the Metastatic Colorectal Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight
Metastatic Colorectal Cancer Emerging Drugs Profile
- Adagrasib (MRTX849): Mirati Therapeutics
- QL-1203: Qilu Pharmaceutical
- ZN-c3: Zentalis Pharmaceuticals
Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 130+ key companies which are developing the therapies for Metastatic colorectal cancer. The Metastatic Colorectal Cancer companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.
Request a sample and discover the recent advances in Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight
Metastatic Colorectal Cancer Drugs and Companies
- ZN-c3: K-Group, Beta Inc
- Cetuximab: Pfizer
- CMAB009 plus Irinotecan: Shanghai Zhangjiang Biotechnology Limited Company
- Irinotecan-only and sequential-CMAB00: Shanghai Biomabs Pharmaceutical Co., Ltd.
- Trifluridin/Tipiracil: Servier Deutschland GmbH
- AB680: Arcus Biosciences Inc
- Etrumadenant: Gilead Sciences
Metastatic Colorectal Cancer Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Metastatic Colorectal Cancer Therapeutics Market include-
Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merc, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
Dive deep into rich insights for drugs for Metastatic Colorectal Cancer Pipeline, click here for Metastatic Colorectal Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight
Scope of the Metastatic Colorectal Cancer Pipeline Report
- Coverage- Global
- Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merc, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
- Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, Oxaliplatin, Leucovorin, Binimetinib, Oxaliplatin, CYAD-101, FOLFOX, Pembrolizumab, Aflibercept, Levofolinate, Irinotecan, and others.
- Metastatic Colorectal Cancer Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Metastatic Colorectal Cancer Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Metastatic colorectal cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Metastatic colorectal cancer Collaboration Deals
- Late Stage Products (Phase III)
- MRTX849: Mirati Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- AK-112: Akeso Biopharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SY 5609: Syros Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic colorectal cancer Key Companies
- Metastatic colorectal cancer Key Products
- Metastatic colorectal cancer- Unmet Needs
- Metastatic colorectal cancer- Market Drivers and Barriers
- Metastatic colorectal cancer- Future Perspectives and Conclusion
- Metastatic colorectal cancer Analyst Views
- Metastatic colorectal cancer Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
